Top

Published in:

01-05-2017 | Neurology and Preclinical Neurological Studies - Original Article

Association between cognitive impairment and urinary dysfunction in Parkinson’s disease

Authors: Zuzanna Tkaczynska, Andrea Pilotto, Sara Becker, Susanne Gräber-Sultan, Daniela Berg, Inga Liepelt-Scarfone

Published in: Journal of Neural Transmission | Issue 5/2017

Abstract

Urinary dysfunction (UD) is a common non-motor feature of Parkinson’s disease (PD), and might be secondary to neurodegeneration involving cortical and subcortical brain areas. The possible link between UD and cognitive deficits has never been examined in frontal cortex impairment, and is still not completely understood in PD. In the present study, 94 PD patients underwent a comprehensive motor, cognitive and non-motor assessment. It was shown that 55.3% of patients reported UD, of which 17% needed specific urological treatment. Patients who reported UD performed worse on global cognition (PANDA, p = .05), visuo-constructive functions (CERAD/praxis, p = .03; and Figure Test, p = .03), and instrumental activities of daily living functions (IADL, p = .03), than patients without UD. The group with UD medication performed worse on global cognition (PANDA, p = .02) and visuo-constructive functions (CERAD/praxis, p = .05; CERAD/praxis recall, p = .05) than the UD group without medication, independent of anticholinergic treatment effect. Our findings suggest an association between cognitive impairment and UD in PD independent from symptomatic treatment.

Available only for authorised users

Araki I, Kuno S (2000) Assessment of voiding dysfunction in Parkinson’s disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry 68:429–433CrossRefPubMedPubMedCentral

Araki I, Kitahara M, Oida T, Kuno S (2000) Voiding dysfunction and Parkinson’s disease: urodynamic abnormalities and urinary symptoms. J Urol 164:1640–1643CrossRefPubMed

Blackett H, Walker R, Wood B (2009) Urinary dysfunction in Parkinson’s disease: a review. Parkinsonism Relat Disord 15:81–87. doi:10.1016/j.parkreldis.2007.10.016 CrossRefPubMed

Campos-Sousa RN, Quagliato E, da Silva BB, de Carvalho RM Jr, Ribeiro SC, de Carvalho DF (2003) Urinary symptoms in Parkinson’s disease: prevalence and associated factors. Arq Neuropsiquiatr 61:359–363CrossRefPubMed

Crispo JA et al (2016) Associations between anticholinergic burden and adverse health outcomes in Parkinson disease. PLoS One 11:e0150621. doi:10.1371/journal.pone.0150621 CrossRefPubMedPubMedCentral

Crook T, Larrabee G (1992) Normative data on a self-rating scale for evaluating memory in everyday life. Arch Clin Neuropsychol 7:41–51CrossRefPubMed

Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314CrossRefPubMed

de Groat WC, Griffiths D, Yoshimura N (2015) Neural control of the lower urinary tract. Compr Physiol 5:327–396. doi:10.1002/cphy.c130056 PubMedPubMedCentral

Dubois B, Burn D, Goetz C, Aarsland C, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lee AS, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow W, Poewe W, Sampaio C, Tolosa E, Emre M (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324CrossRefPubMed

Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D (2010) Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study. J Neurol Neurosurg Psychiatry 81:160–165. doi:10.1136/jnnp.2009.186239 CrossRefPubMed

Fahn S, Elton RL, Members of the UPDRS Development Committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease, vol 2. Macmillan Health care Information, Florham Park, NJ, pp 153–164

Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB (2015) New clinical subtypes of parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 72:863–873. doi:10.1001/jamaneurol.2015.0703 CrossRefPubMed

Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198CrossRefPubMed

Fowler CJ, Griffiths DJ (2010) A decade of functional brain imaging applied to bladder control. Neurourol Urodyn 29:49–55. doi:10.1002/nau.20740 PubMed

Graf C (2009) The Lawton instrumental activities of daily living (IADL) scale. Medsurg Nurs 18:315–316PubMed

Haerting C, et al (2000) Wechsler Gedächtnisstest-revidierte Fassung deutsche Adaptation der revidierten Fassung der Wechsler Memory scale. Huber, Bern, Switzerland

Hautzinger M, Bailer M, Worall H, Keller F (1995) Beck-Depressions-Inventar (BDI), vol 2. Huber, Bern

Kalbe E (2007) Sensitivity and specificity of the “Parkinson Neuropsychometric Dementia Assessment” (PANDA): Results of the GEPAD-Study. Aktuelle Neurologie 34:140–146CrossRef

Kitta T, Chancellor MB, de Groat WC, Shinohara N, Yoshimura N (2016) Role of the anterior cingulate cortex in the control of micturition reflex in a rat model of Parkinson’s disease. J Urol 195:1613–1620. doi:10.1016/j.juro.2015.11.039 CrossRefPubMed

Leroi I, McDonald K, Pantula H, Harbishettar V (2012) Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J Geriatr Psychiatry Neurol 25:208–214. doi:10.1177/0891988712464823 CrossRefPubMed

Liepelt-Scarfone I (2007) Der Berliner-Apraxie-Test für ideomotorische und ideatorische Apraxie - Bestimmung der Itemkennwerte. Zeitschrift für Neuropsychologie 18(3):193–206CrossRef

Liepelt-Scarfone I et al (2012) Cognitive profiles in Parkinson’s disease and their relation to dementia: A data-driven approach. Int J Alzheimers Dis 2012:910757. doi:10.1155/2012/910757 PubMedPubMedCentral

Liepelt-Scarfone I et al (2015) Autonomic dysfunction in subjects at high risk for Parkinson’s disease. J Neurol 262:2643–2652. doi:10.1007/s00415-015-7888-z CrossRefPubMed

Litvan I et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord Off J Mov Disord Soc 27:349–356. doi:10.1002/mds.24893 CrossRef

Martinez-Martin P, Falup-Pecurariu C, Rodriguez-Blazquez C, Serrano-Duenas M, Carod Artal FJ, Rojo Abuin JM, Aarsland D (2011) Dementia associated with Parkinson’s disease: applying the Movement Disorder Society Task Force criteria. Parkinsonism Relat Disord 17:621–624. doi:10.1016/j.parkreldis.2011.05.017 CrossRefPubMed

Memory Clinic-NPZ (2005) The consortium to establish a registry of Alzheimer’s disease CERAD-plus. Basel Memory Clinic-NPZ, Basel

Oswald WD, Fleischmann UM (1999) Nurnberger-Alters-Inventar (NAI), vol 4. Hogrefe, Gottingen, Germany

Pilleri M, Koutsikos K, Antonini A (2013) Is there room for new non-dopaminergic treatments in Parkinson’s disease? J Neural Transm 120:349–352. doi:10.1007/s00702-012-0947-z CrossRefPubMed

Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE (2008) The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 168:508–513. doi:10.1001/archinternmed.2007.106 CrossRefPubMed

Sakakibara R, Uchiyama T, Yamanishi T, Shirai K, Hattori T (2008) Bladder and bowel dysfunction in Parkinson’s disease. J Neural Transm 115:443–460. doi:10.1007/s00702-007-0855-9 CrossRefPubMed

Sakakibara R, Tateno F, Kishi M, Tsuyuzaki Y, Uchiyama T, Yamamoto T (2012) Pathophysiology of bladder dysfunction in Parkinson’s disease. Neurobiol Dis 46:565–571. doi:10.1016/j.nbd.2011.10.002 CrossRefPubMed

Sakakibara R et al (2013) Depression, anxiety and the bladder. Low Urin Tract Symptoms 5:109–120. doi:10.1111/luts.12018 CrossRefPubMed

Sakakibara R et al (2014) Bladder function of patients with Parkinson’s disease. Int J Urol 21:638–646. doi:10.1111/iju.12421 CrossRefPubMed

Smith M, Seth J, Batla A, Hofereiter J, Bhatia KP, Panicker JN (2016) Nocturia in patients with Parkinson's disease. Mov Disord Clinical Practice 3:168–172CrossRef

Tateno F et al (2015) Lower urinary tract function in dementia with Lewy bodies (DLB). Mov Disord Off J Mov Disord Soc 30:411–415. doi:10.1002/mds.25985 CrossRef

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord Off J Mov Disord Soc 25:2649–2653. doi:10.1002/mds.23429 CrossRef

Toucha, L (2004) Turm von London – Deutsche Version TL-D. Hogrefe, Göttingen

Uchiyama T et al (2011) Urinary dysfunction in early and untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry 82:1382–1386. doi:10.1136/jnnp.2011.241075 CrossRefPubMed

Warrington EK, James M (1991) The visual object and space perception battery. Thames Valley Test Company, Bury St Edmunds

Wenning GK, Tison F, Seppi K, et al (2004) Development and validation of the unified multiple system atrophy rating scale. Mov Disord Off J Mov Disord Soc 19:1391–1402. doi:10.1002/mds.20255

Winge K, Fowler CJ (2006) Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord Off J Mov Disord Soc 21:737–745. doi:10.1002/mds.20867 CrossRef

Winge K, Nielsen KK (2012) Bladder dysfunction in advanced Parkinson’s disease. Neurourol Urodyn 31:1279–1283. doi:10.1002/nau.22237 CrossRefPubMed

Winge K, Werdelin LM, Nielsen KK, Stimpel H (2004) Effects of dopaminergic treatment on bladder function in Parkinson’s disease. Neurourol Urodyn 23:689–696. doi:10.1002/nau.20054 CrossRefPubMed

Winge K, Skau AM, Stimpel H, Nielsen KK, Werdelin L (2006) Prevalence of bladder dysfunction in Parkinsons disease. Neurourol Urodyn 25:116–122. doi:10.1002/nau.20193 CrossRefPubMed

Yamamoto T et al (2009) Questionnaire-based assessment of pelvic organ dysfunction in multiple system atrophy. Mov Disord 24(7):972–978. doi:10.1002/mds.22332 CrossRefPubMed

Zimmermann P, Fimm B (2002) A test battery for attentional performance (version 1.7). Psytests, Herzogenrath

Title: Association between cognitive impairment and urinary dysfunction in Parkinson’s disease
Authors: Zuzanna Tkaczynska
Andrea Pilotto
Sara Becker
Susanne Gräber-Sultan
Daniela Berg
Inga Liepelt-Scarfone
Publication date: 01-05-2017
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 5/2017
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-017-1690-2

At a glance: The STEP trials

Springer Medicine

Association between cognitive impairment and urinary dysfunction in Parkinson’s disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2017

Psychomotor effect differences between l-methamphetamine and d-methamphetamine are independent of murine plasma and brain pharmacokinetics profiles

Differential diagnosis between patients with probable Alzheimer’s disease, Parkinson’s disease dementia, or dementia with Lewy bodies and frontotemporal dementia, behavioral variant, using quantitative electroencephalographic features

Arterial spin labelling detects posterior cortical hypoperfusion in non-demented patients with Parkinson’s disease

Post-reexposure administration of d-cycloserine facilitates reconsolidation of contextual conditioned fear memory in rats

Dopamine, T cells and multiple sclerosis (MS)

The missing link between sleep disorders and age-related dementia: recent evidence and plausible mechanisms